Host-Response

MBio is developing a family of point-of-care, multiplex tests for host-response biomarkers in blood. Host-response biomarkers can be measured early in acute infection. Research indicates that certain combinations of these biomarkers may be prognostic for cytokine storm and associated bad outcomes in COVID-19 and sepsis. Our panels will provide rapid results that may give insights about immune response, help inform treatment decisions and direct resource allocation in a crisis. 

The LightDeck IL-6 Test is available for research us. Interleukin-6 is one marker in the cytokine storm that is prognostic for bad outcomes in sepsis and COVID-19.

Sepsis Facts

Worldwide

Affects 30 million people, 6 million deaths annually.

Speed matters

Sepsis can progress rapidly and can be fatal if not treated quickly. Each hour of delay in giving antibiotics increases risk of death by 7%.

High cost, morbidity and mortality

Costs $27 billion in the U.S.

Clinical Utility of MBio Host-Response Panels

Intended UseAction
Diagnosis: Differentiate between infectious vs. non-infectious etiologyDetermine the need for broad spectrum antibiotics vs. COVID-19 intervention vs. non-infectious intervention
Staging: Where the patient is on the disease continuum: low-risk to cytokine storm?Guide aggressiveness of treatment and resource allocation for optimal outcomes at lower cost
Monitoring: Assess response to treatmentCan antibiotics be de-escalated? Should treatment be more aggressive?

Products are for research use only or under development and not available for sale.

MBio Diagnostics

5603 Arapahoe Avenue, Suite 1 | Boulder, CO | 80303 USA
Ph. (303) 952-2905 | info@mbiodx.com |

Privacy Policy  |  Terms of UseLinkedIn